
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: a new option beyond steroids, a cancer vaccine that extended survival in phase 3, and a well-funded bet on treating blood disorders without stem cell transplants.
First,
Next,
And finally,
That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key takeaways
- Steroid sparing: Cosentyx is now the second biologic approved for polymyalgia rheumatica, joining sarilumab.
- Survival benefit: REGAL is a rare phase 3 overall survival win for a peptide cancer vaccine, though the full data haven’t been peer reviewed.
- In vivo delivery: Marrow is betting antibody-guided delivery can reach blood stem cells without transplant, which hasn’t been shown in humans yet.
Related to this article









